



PATIENT SAVINGS PROGRAM PAY AS LITTLE AS \$4*

BIN: 600428 PCN: 06780000 GROUP: 06780099

ID: 69996760301

*Terms and conditions apply.

This card is not health insurance and will be accepted only at participating pharmacies.

Please see <u>full Prescribing Information</u>, including **Boxed Warning** and the <u>Patient Medication Guide</u>. Ensure the Medication Guide is provided to the patient.

To Patient: Take this card, along with your prescription, to your pharmacist to receive Baxdela at a reduced copay amount.

<u>To Pharmacist</u>: For Insured Patients: Process a Coordination of Benefits (COB/split bill) claim using the patient's prescription insurance for the PRIMARY claim. Submit a SECONDARY (OCC 3 or 8) claim using BIN: 600428/PCN: 06780000.

For pharmacy processing questions, please call 1-877-528-4996.

(Monday – Friday 24 hours, Saturday 8 AM – 7 PM EST, and Sunday 9 AM – 5 PM EST)

*Terms and Conditions:

- · Most patients will pay as little as \$4 and no more than \$75 for out-of-pocket expenses with use of this offer. Maximum dollar value may apply.
- This offer is valid for Baxdela 450 mg tablets.
- Patients must be 18 years of age or older.
- This offer is valid for one prescription.
- Patients must be covered by commercial insurance pharmacy benefits.
- No other purchase is necessary.
- This offer may not be valid in Massachusetts and California.
- This offer is not transferable. No substitutions are permitted. The offer cannot be combined with any other coupon, free trial, discount, prescription savings card, or other offer.
- This offer is not insurance.
- This offer must be accompanied with a valid prescription for Baxdela 450 mg tablets.

Pharmacy and patient shall not submit (i) a claim for reimbursement for Product to any public or private third-party payer or any federal or state healthcare program, including but not limited to Medicaid, Medicare, Medigap, Department of Defense (DoD), Veterans Affairs (VA), TRICARE, CHAMPUS, Puerto Rico Government Health Insurance, or any state patient or pharmaceutical assistance program; or (ii) a claim for any portion of Product to a third-party payer for purposes of counting it toward the patient's out-of-pocket costs in any private insurance plan or federal or state healthcare program. Pharmacy will comply with all applicable state laws and any obligations, contractual or otherwise, that it has as a pharmacy provider. Patient shall not seek or accept co-payment assistance from a copay foundation or otherwise for Product. This offer has its own unique ID number, is not transferable, is limited to one per person and may not be combined with any other offer. If the card is lost prior to use, simply print or download a new copy at www.Baxdela.com and bring it to the Pharmacy along with a valid prescription.

Offer good only in the United States. Void where prohibited by law, taxed, or restricted. May not be used with any other discount, trial offer, or other offer. Melinta Therapeutics, Inc. reserves the right to rescind, revoke, or amend this program without notice.

INDICATIONS & USAGE:

BAXDELA (delafloxacin) is a fluoroquinolone antibacterial indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of BAXDELA and other antibacterial drugs, BAXDELA should be used only to treat ABSSSI that are proven or strongly suspected to be caused by bacteria.

IMPORTANT SAFETY INFORMATION:

WARNING: SERIOUS ADVERSE REACTIONS INCLUDING TENDINITIS, TENDON RUPTURE, PERIPHERAL NEUROPATHY, CENTRAL NERVOUS SYSTEM EFFECTS, and EXACERBATION OF MYASTHENIA GRAVIS

Fluoroquinolones have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together, including:

- Tendinitis and tendon rupture
- Peripheral neuropathy
- Central nervous system effects

Discontinue BAXDELA immediately and avoid the use of fluoroquinolones, including BAXDELA, in patients who experience any of these serious adverse reactions.

Fluoroquinolones may exacerbate muscle weakness in patients with myasthenia gravis. Avoid BAXDELA in patients with known history of myasthenia gravis.

Contraindications

BAXDELA is contraindicated in patients with known hypersensitivity to BAXDELA or other fluoroquinolones.

Warnings and Precautions

Risk of tendinitis, tendon rupture, peripheral neuropathy, and central nervous system effects is increased with use of fluoroquinolones. Discontinue BAXDELA immediately at the first signs or symptoms of any of these serious adverse reactions.

Avoid BAXDELA in patients with known history of myasthenia gravis.

Hypersensitivity reactions may occur after first or subsequent doses of BAXDELA. Discontinue BAXDELA at the first sign of hypersensitivity.

Clostridium difficile-associated diarrhea has been reported in users of nearly all systemic antibacterial drugs, including BAXDELA. Evaluate if diarrhea occurs.

Prescribing BAXDELA in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Adverse Reactions

The most common adverse reactions in patients treated with BAXDELA were nausea (8%), diarrhea (8%), headache (3%), transaminase elevations (3%), and vomiting (2%).

Use in Specific Populations

In patients with severe renal impairment (eGFR of 15-29 mL/min/1.73 m²), the dosage of BAXDELA should be decreased to 200 mg IV every 12 hours or 450 mg orally every 12 hours. BAXDELA is not recommended in patients with End Stage Renal Disease [ESRD] (eGFR of <15 mL/min/1.73 m²) due to insufficient information to provide dosing recommendations.

Please see <u>full Prescribing Information</u>, including **Boxed Warning** and the <u>Patient Medication Guide</u>. Ensure the Medication Guide is provided to the patient.